Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1

Summary

Heparanase, known to be involved in angiogenesis and metastasis, was shown to form a complex with tissue factor (TF) and to enhance the generation of factor Xa. Platelets and granulocytes contain abundant amounts of heparanase that may enhance the coagulation system upon discharge. It was the aim of this study to identify the inducer and pathway of heparanase release from these cells. Platelets and granulocytes were purified from pooled normal plasma and were incubated with ATP, ADP, epinephrine, collagen, ristocetin, arachidonic acid, serotonin, LPS and thrombin. Heparanase levels were assessed by ELISA, heparanase procoagulant activity assay and western blot analysis. The effects of selective protease-activated receptor (PAR)-1 and 2 inhibitors and PAR-1 and 4 activators were studied. An in-house synthesised inhibitory peptide to heparanase was used to evaluate platelet heparanase involvement in activation of the coagulation system. Heparanase was released from platelets only by thrombin induction while other inducers exerted no such effect. The heparanase level in a platelet was found to be 40 % higher than in a granulocyte. Heparanase released from platelets or granulocytes increased factor Xa generation by three-fold. PAR-1 activation via ERK intracellular pathway was found to induce heparanase release. In conclusion, heparanase is selectively released from platelets and granulocytes by thrombin interacting with PAR-1. Heparanase derived from platelets and granulocytes is involved in activation of the extrinsic coagulation pathway. The present study implies on a potential anticoagulant effect, in addition to anti-platelet effect, of the new clinically studied PAR-1 inhibitors.

Keywords

Heparanase - thrombin - protease activated receptors (PAR) - platelets - granulocytes

^* Equal contribution of authors.

• References

• 1 Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-1350.
• 2 Pikas DS, Li JP, Vlodavsky I. et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-1877.
• 3 Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-M108.
• 4 Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-347.
• 5 Nadir Y, Brenner B, Zetser A. et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4: 2443-2451.
• 6 Nadir Y, Brenner B, Gingis-Velitski S. et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 2008; 99: 133-141.
• 7 Nadir Y, Brenner B, Fux L. et al. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95: 1927-1934.
• 8 Zetser A, Levy-Adam F, Kaplan V. et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258.
• 9 Nadir Y, Kenig Y, Drugan A. et al. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011; 128: e3-e8.
• 10 Shafat I, Zcharia E, Nisman B. et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958-963.
• 11 Axelman E, Henig I, Crispel Y. et al. Novel peptides that inhibit heparanase activation of the coagulation system. Thromb Haemost 2014; 112: 466-477.
• 12 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
• 13 Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014; 123: 2605-2613.
• 14 Howells GL, Macey MG, Chinni C. et al. Proteinase-activated receptor-2: expression by human neutrophils. J Cell Sci 1997; 110: 881-887.
• 15 Colognato R, Slupsky JR, Jendrach M. et al. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102: 2645-2652.
• 16 Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 2006; 281: 23804-23811.
• 17 Coppens M, Eikelboom JW, Gustafsson D. et al. Translational success stories: development of direct thrombin inhibitors. Circ Res 2012; 111: 920-929.
• 18 Estevez B, Kim K, Delaney MK. et al. Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 2016; 127: 626-636.
• 19 Morrow DA, Braunwald E, Bonaca MP. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
• 20 Sen P, Gopalakrishnan R, Kothari H. et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011; 117: 3199-3208.
• 21 Belham CM, Tate RJ, Scott PH. et al. Trypsin stimulates proteinase-activated receptor-2-dependent and -independent activation of mitogen-activated protein kinases. Biochem J 1996; 320: 939-946.
• 22 Yu Z, Ahmad S, Schwartz JL. et al. Protein-tyrosine phosphatase SHP2 is positively linked to proteinase-activated receptor 2-mediated mitogenic pathway. J Biol Chem 1997; 272: 7519-7524.
• 23 Wang L, Luo J, Fu Y. et al. Induction of interleukin-8 secretion and activation of ERK1/2, p38 MAPK signaling pathways by thrombin in dermal fibroblasts. Int J Biochem Cell Biol 2006; 38: 1571-1583.
• 24 McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol 2010; 77: 1005-1015.
• 25 Nadal-Wollbold F, Pawlowski M, Levy-Toledano S. et al. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531: 475-482.
• 26 Rosado JA, Sage SO. Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets. J Biol Chem 2001; 276: 15659-15665.
• 27 Hakkim A, Fuchs TA, Martinez NE. et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 2011; 7: 75-77.
• 28 Lupu C, Westmuckett AD, Peer G. et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 2005; 167: 1161-1172.
• 29 Katz BZ, Muhl L, Zwang E. et al. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms. Thromb Haemost 2007; 98: 1193-1199.
• 30 Holmsen H, Day HJ. The selectivity of the thrombin-induced platelet release reaction: subcellular localization of released and retained constituents. J Lab Clin Med 1970; 75: 840-855.
• 31 Holmsen H. Platelet metabolism and activation. Semin Hematol 1985; 22: 219-240.
• 32 Ciferri S, Emiliani C, Guglielmini G. et al. Platelets release their lysosomal content in vivo in humans upon activation. Thromb Haemost 2000; 83: 157-164.
• 33 Siller-Matula JM, Schwameis M, Blann A. et al. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011; 106: 1020-1033.